Medication-info.com Search Menu

Navitrux: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
150 mg/5 mL
Other brand names:
Drug class:
Active ingredient:
Similar drugs:

Source: FDA drug labeling via NLM DailyMed · About this document

Patient information: uses, side effects, how to take - Navitrux

What is NAVITRUX?

NAVITRUX is a prescription medicine used with other medicines that treat nausea and vomiting in people 6 months of age and older to prevent nausea and vomiting caused by certain anti-cancer (chemotherapy) medicines.

  • NAVITRUX is not used to treat nausea and vomiting that you already have.

  • It is not known if NAVITRUX is safe and effective in children less than 6 months of age.

Do not receive NAVITRUX if you:

  • are allergic to fosaprepitant, aprepitant, or any of the ingredients in NAVITRUX. See the end of this Patient Information leaflet for a complete list of the ingredients in NAVITRUX.
  • are taking pimozide (ORAP).

Before receiving NAVITRUX, tell your healthcare provider if you:

  • have liver problems.

  • are pregnant or plan to become pregnant. It is not known if NAVITRUX can harm your unborn baby.

  • Women who use birth control medicines containing hormones to prevent pregnancy (birth control pills, skin patches, and implants) should also use a backup method of birth control that does not contain hormones, such as condoms and spermicides, during treatment with NAVITRUX and for 1 month after receiving NAVITRUX or aprepitant taken by mouth (oral).
  • are breastfeeding or plan to breastfeed. It is not known if NAVITRUX passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive NAVITRUX.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

NAVITRUX may affect the way other medicines work, and other medicines may affect the way NAVITRUX works, causing serious side effects.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How will I receive NAVITRUX?

Adults 18 years of age and older:

NAVITRUX will be given on Day 1 of chemotherapy treatment. It will be given to you by intravenous (IV) infusion in your vein about 50 to 60 minutes before you start your chemotherapy treatment.

Children 6 months to 17 years of age:

NAVITRUX will be given to your child by intravenous (IV) infusion into a large vein through a type of IV line called a central venous catheter, about 1 hour to 1 ½ hours before the start of their chemotherapy treatment. Depending on the chemotherapy treatment, there are 2 ways that NAVITRUX may be given:

  1. 1. NAVITRUX is given on Day 1 only (single day of chemotherapy).
  2. 2. NAVITRUX is given on Days 1, 2, and 3 (single or multiple days of chemotherapy).
  3. ● Your child may receive capsules of aprepitant or an oral suspension of aprepitant instead of NAVITRUX on Days 2 and 3. If your child will receive either of these, see the Patient Information for aprepitant capsules or aprepitant for oral suspension for further information.

If you take the blood thinner medicine warfarin sodium (COUMADIN, JANTOVEN), your healthcare provider may do blood tests after you receive NAVITRUX to check your blood clotting.

What are the possible side effects of NAVITRUX?

NAVITRUX may cause serious side effects, including:

  • Serious allergic reactions. Allergic reactions can happen with fosaprepitant given by intravenous (IV) infusion and may be serious. Tell your healthcare provider right away if you have hives, rash, itching, flushing or redness of your face or skin, trouble breathing or swallowing, dizziness, a rapid or weak heartbeat, or you feel faint during or soon after you receive NAVITRUX, as you may need emergency medical care.

Severe skin reactions, which may include rash, skin peeling, or sores, may occur.

  • Infusion site reactions (ISR) at or near the infusion site have happened with fosaprepitant given by intravenous (IV) infusion . Most severe ISR have happened with a certain type of chemotherapy medicine that can burn or blister your skin (vesicant) with side effects, including pain, swelling and redness. Death of skin tissue (necrosis) has happened in some people getting this type of chemotherapy medicine. Most ISR can happen with the first, second, or third dose and some can last up to 2 weeks or longer. Tell your healthcare provider right away if you get any infusion site side effects.

In adults, the most common side effects of NAVITRUX include:

  • tiredness
  • feeling weak or numb in your arms and legs
  • diarrhea
  • painful, difficult, or changes in your digestion (dyspepsia)
  • low white blood cell and red blood cell counts
  • urinary tract infection
  • weakness
  • pain in your arms and legs

In children 6 months to 17 years of age, the most common side effects of NAVITRUX include:

  • low red blood cell count
  • low blood platelet count
  • low white blood cell count
  • low white blood cell count with a fever

These are not all of the possible side effects of NAVITRUX.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of NAVITRUX.

If you would like more information about NAVITRUX, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about NAVITRUX that is written for health professionals.

What are the ingredients in NAVITRUX?

Active ingredient: fosaprepitant

Inactive ingredients: anhydrous lactose, edetate disodium, polysorbate 80 and sodium hydroxide (for pH adjustment)

Manufactured for:

Avyxa Pharma, LLC

New Jersey 07054, USA

Made in China

The brands listed in the above sections "Do not receive NAVITRUX if you:" and "How will I receive NAVITRUX?" are the registered trademarks of their respective owners and are not trademarks of Avyxa Pharma, LLC

For more information about NAVITRUX call 1-888-520-0954.

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 220436 · View the label on DailyMed

Revision date stated in the text: June 2026

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Navitrux

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Drug class Substance P/Neurokinin-1 Receptor Antagonist
Active ingredient Fosaprepitant dimeglumine 150 mg/5 mL
Dosage form Injection, powder, lyophilized, for solution
Route Intravenous
Marketing status listed in the FDA NDC Directory
Company (applicant) AVYXA HOLDINGS
FDA approval NDA 220436New Drug Application (NDA) Approved June 24, 2026
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
150 mg/5 mL – 5 ml in 1 vial / 1 in 1 carton NDC 83831-153-01

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.